The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623)

Pharmaceutical Research

Volumn 27, Issue 5, 2010, Pages 878-893

  Trevaskis, Natalie L ^a   McEvoy, Claire L ^a   Mcintosh, Michelle P ^a   Edwards, Glenn A ^b   Shanker, Ravi M ^c   Charman, William N ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PFIZER INC   (United States)

Author keywords

Absorption; CETP inhibitor; Intestine; Lymphatic transport; Torcetrapib

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CP 524515; CP 532623; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; FOOD; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE LYMPH; LIPID TRANSPORT; LIPOPHILICITY; LYMPH FLOW; LYMPHATIC SYSTEM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; AMINOQUINOLINES; ANIMALS; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBAMATES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FOOD-DRUG INTERACTIONS; HALF-LIFE; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTESTINES; LIPIDS; LYMPHATIC SYSTEM; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; QUINOLINES; SOLUBILITY; TRIGLYCERIDES;

EID: 77953270848     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0083-0     Document Type: Article

References (52)

1. Shah PK. Inhibition, of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J. 2007; 28:5-12.
2. El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ. The role of CETP inhibition in dyslipidemia, Curr Atheroscler Rep. 2007; 9:125-133
3. Boekholdt SM, Kuivenhoven JA, Hovingh GK, Jukema JW, Kastelein JJ, van Tol A. CETP gene variation: relation to lipid parameters and cardiovascular risk. Curr Opin Lipidol. 2004; 15:393-398
4. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008; 299:2777-2788 (Pubitemid 351846853)
5. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105:2159-2165
6. Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol. 2006; 26:706-715 (Pubitemid 43732142)
7. Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm. F, Trip MD, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia, Am J Cardiol. 2005; 95:1085-1088 (Pubitemid 40544314)
8. Howes LG, Kostner K. The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism, Expert Opin Investig Drugs. 2007; 16:1509-1516 (Pubitemid 350028403)
9. Blasi E, Bamberger M, Knight D, Engwall M, Wolk R, Winter S, et al. Effects of CP-532, 623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J Cardiovasc Pharmacol. 2009; 53:507-516
10. Clark RW, Ruggeri RB, Cunningham. D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006; 47:537-552 (Pubitemid 43345595)
11. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007; 6:231-248
12. Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008; 60:625-637
13. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur J Pharm Sci. 2006; 29:278-287
14. Serajuddin AT. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm. Sci. 1999; 88:1058-1066
15. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008; 60:702-716
16. Khoo S, Edwards GA, Porter CJH, Charman WN. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001; 90:1599-1607 (Pubitemid 32979754)
17. Khoo SM, Shackleford DM, Porter CJ, Edwards GA, Charman WN. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res. 2003; 20:1460-1465
18. Phan CT, Tso P. Intestinal lipid absorption and transport. Front Biosci. 2001; 6:D299-319.
19. Charman WN, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986; 34:175-178
20. Holm R, Hoest J. Successful in silico predicting of intestinal lymphatic transfer. Int J Pharm. 2004; 272:189-193 (Pubitemid 38293024)
21. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived, isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005; 26:394-404. (Pubitemid 41551573)
22. Gershkovich P, Fanous J, Qadri B, Yacovan A, Amselem S, Hoffman A. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. J Pharm Pharmacol. 2009; 61:31-39
23. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov. 2008; 7:84-99.
24. Porter CJH, Charman WN. Intestinal lymphatic transport: an update. Adv Drug Deliv Rev. 2001; 50:61-80.
25. Lombardo F, Shalaeva MY, Tupper KA, Gao F. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J Med Chem. 2001; 44:2490-2497
26. Donovan SF, Pescatore MC. Method for measuring the logarithm of the octanol-water partition coefficient by using short octadecyl-poly (vinyl alcohol) high-performance liquid chromatography columns. J Chromatogr A. 2002; 952:47-61.
27. Edwards GA, Porter CJ, Caliph SM, Khoo SM, Charman WN. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev. 2001; 50:45-60.
28. Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Porter CJ, et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther. 2003; 306:925-933 (Pubitemid 37025297)
29. Rane SS, Anderson BD. What determines drug solubility in lipid vehicles: is it predictable? Adv Drug Deliv Rev. 2008; 60:638-656
30. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000; 44:235-249
31. Khoo S, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm. 1998; 167:155-164 (Pubitemid 28341517)
32. Porter CJ, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004; 21:1405-1412
33. Grove M, Nielsen JL, Pedersen GP, Mullertz A. Bioavailability of seocaldtol IV: evaluation of lymphatic transport in conscious rats. Pharm Res. 2006; 23:2681-2688 (Pubitemid 44691615)
34. Griffin BT, O'Driscoll CM. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. J Pharm Pharmacol. 2006; 58:917-925
35. Gershkovich P, Qadri B, Yacovan A, Amselem S, Hoffman A. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211, 220. Eur J Pharm Sci. 2007; 31:298-305. (Pubitemid 47079000)
36. Charman WN, Stella VJ. Lymphatic transport of drugs. Boca Raton: CRC; 1992.
37. Trevaskis NL, Porter CJ, Charman WN. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J Pharmacol Exp Ther. 2006; 316:881-891
38. Inazu A, Nakajima K, Nakano T, Niimi M, Kawashiri MA, Nohara A, et al. Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. Atherosclerosis 2008; 196:953-957
39. Guerin M, Le Goff W, Duchene E, Julia Z, Nguyen. T, Thuren T, et al. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vase Biol, 2008; 28:148-154
40. Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol. 2006; 26:1350-1356 (Pubitemid 44305381)
41. Guyard-Dangremont V, Desrumaux C, Gambert P, Lallemant C, Lagrost L. Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility. Comp Biochem Physiol B Biochem. Mol Biol. 1998; 120:517-525
42. Tsutsumi K, Hagi A, Inoue Y. The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. Biol Pharm Bull. 2001; 24:579-581 (Pubitemid 32499491)
43. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993; 34:1255-1274
44. Alonso AL, Zentella-Dehesa A, Mas-Oliva J. Characterization of a naturally occurring new version of the cholesterol ester transfer protein (CETP) from small intestine. Mol Cell Biochem. 2003; 245:173-182 (Pubitemid 36416834)
45. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000; 148:1-15.
46. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 2003; 44:22-32. (Pubitemid 36114766)
47. Cartwright IJ, Plonne D, Higgins JA. Intracellular events in the assembly of chylomicrons in rabbit enterocytes. J Lipid Res. 2000; 41:1728-1739
48. Beamer IJ. Structure of human BPI (bactericidal/permeabilityincreasing protein) and implications for related proteins. Biochem. Soc Trans. 2003; 31:791-794
49. Beamer LJ, Fischer D, Eisenberg D. Detecting distant relatives of mammalian LPS-binding and lipid transport proteins. Protein Sci, 1998; 7:1643-1646 (Pubitemid 28331287)
50. Qiu X, Mistiy A, Ammirati MJ, Chrunyk BA, Clark RW, Cong Y, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 2007; 14:106-113
51. Jiang XC, Li Z, Liu R, Yang XP, Pan M, Lagrost L, et al. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem. 2005; 280:18336-18340 (Pubitemid 41389080)
52. Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Lankhuizen I, et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res. 2002; 43:1875-1880 (Pubitemid 35315805)